A novel cell line generated using the CRISPR /Cas9 technology as universal quality control material for KRAS G12V mutation testing

Background KRAS mutations are the key indicator for EGFR monoclonal antibody‐targeted therapy and acquired drug resistance, and their accurate detection is critical to the clinical decision‐making of colorectal cancer. However, no proper quality control material is available for the current detection methods, particularly next‐generation sequencing ( NGS ). The ideal quality control material for NGS needs to provide both the tumor mutation gene and the matched background genomic DNA , which is uncataloged in public databases, to accurately distinguish germline polymorphisms and somatic mutations. Methods We developed a novel KRAS G12V mutant cell line using the clustered regularly interspaced short palindromic repeat ( CRISPR )/ CRISPR ‐associated protein 9 (Cas9) technique to make up for the deficiencies in existing quality control material and further validated the feasibility of the cell line as quality control material by amplification refractory mutation system ( ARMS ), Sanger sequencing, digital PCR ( dPCR ), and NGS . Results We verified that the edited cell line specifically had the G12V mutation, and the validation results presented a high consistency among the four methods of detection. The three cell lines screened contained the G12V mutation and the mutation allele fractions of G12V‐1, G12V‐2, and G12V‐3 were 52.01%, 82.06%, and 17.29%, respectively. Conclusion The novel KRAS G12V cell line generated using the CRISPR /Cas9 gene editing system is suitable as a quality control material for all current detection methods and provides a new direction in the development of quality control material.